143 results match your criteria: "ICM (Brain and Spine Institute) Pitié-Salpêtrière Hospital[Affiliation]"

High levels of neurofilament light and YKL-40 in cerebrospinal fluid are related to poor outcome in ALS.

J Neurol Sci

August 2024

Department of Neurology, Institute of Clinical Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. Electronic address:

Amyotrophic lateral sclerosis (ALS) is a neurological disease without effective treatment. No pathognomonic test can diagnose ALS in sporadic cases. Routine investigation in suspected cases includes neurological examination, imaging of the brain and spine and electromyography supported by blood and cerebrospinal fluid (CSF) analyses.

View Article and Find Full Text PDF

Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis.

JAMA Neurol

August 2024

Nantes Université, l'Institut national de la santé et de la recherche médicale, CHU de Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, CIC l'Institut national de la santé et de la recherche médicale 1413, Service de Neurologie, Nantes, France.

Article Synopsis
  • * Conducted over eight years (2015-2023) using data from a French MS registry, researchers categorized relapses based on MRI results to better understand their impact.
  • * Findings indicate that certain factors, like treatment type and fatigue, increase the likelihood of clinically defined relapses without MRI evidence, suggesting a need for revised monitoring and treatment strategies for MS patients.
View Article and Find Full Text PDF

Purpose: Repetitive transcranial magnetic stimulation (rTMS) can enhance aphasia recovery. Most studies have used inhibitory stimulation targeting the right inferior frontal gyrus. However, the motor cortex, observed to contribute to the prediction of aphasia recovery, is involved in word production and could be an appropriate target for rTMS.

View Article and Find Full Text PDF

The pattern of cortical thickness associated with executive dysfunction in MCI and SCC: The MEMENTO cohort.

Rev Neurol (Paris)

December 2024

Department of Neurology and Functional Neuroscience and Pathology Laboratory, Jules-Verne University of Picardy, Amiens University Hospital, CHU de Amiens-Picardie, 80054 Amiens, France.

Background: The association between the pattern of cortical thickness (CT) and executive dysfunction (ED) in mild cognitive impairment (MCI) and subjective cognitive complaints (SCC) is still poorly understood. We aimed to investigate the association between CT and ED in a large French cohort (MEMENTO) of 2323 participants with MCI or SCC.

Methods: All participants with available CT and executive function data (verbal fluency and Trail Making Test [TMT]) were selected (n=1924).

View Article and Find Full Text PDF

Transcranial magnetic stimulation to improve aphasia after right hemispheric stroke: A single case experimental design.

Ann Phys Rehabil Med

September 2024

Faculty of Psychology and Educational Sciences, University of Geneva, 40 bd du Pont-d'Arve, 1211 Genève 4, Switzerland; Neurorehabilitation Unit, Department of Clinical Neurosciences, Vaudois University Hospital Center and University of Lausanne, 46 rue du Bugnon, 1011 Lausanne, Switzerland.

View Article and Find Full Text PDF

Non-Hodgkin lymphomas (NHL) commonly occur in immunodeficient patients, both those infected by human immunodeficiency virus (HIV) and those who have been transplanted, and are often driven by Epstein-Barr virus (EBV) with cerebral localization, raising the question of tumor immunogenicity, a critical issue for treatment responses. We investigated the immunogenomics of 68 lymphoproliferative disorders from 51 immunodeficient (34 post-transplant, 17 HIV+) and 17 immunocompetent patients. Overall, 72% were large B-cell lymphoma and 25% were primary central nervous system lymphoma, while 40% were EBV+.

View Article and Find Full Text PDF

Introduction: Both intracranial pressure (ICP) and cerebral arterial blood volume (CBV) have a pulsatile character related to the cardiac cycle. The evolution of the shape of ICP pulses under increasing ICP or decreasing intracranial compliance is well documented. Nevertheless, the exact origin of the alterations in the ICP morphology remains unclear.

View Article and Find Full Text PDF

We report here about two novel tumours classified as extraventricular neurocytomas (EVN) using DNA-methylation profiling, associated with NTRK2 fusions instead of the usual FGFR1 alterations so far attributed to this tumoural entity. We present the second detailed case of an intraventricular presentation in the MC EVN. Our findings broaden the spectrum of MC EVN and have implications in terms of diagnosis, therapy and terminology.

View Article and Find Full Text PDF

The biological sample collection of the OFSEP French MS registry: An essential tool dedicated to researchers.

Mult Scler Relat Disord

September 2023

Nantes University Hospital, Neurology Department, CRC-SEP, Nantes University, INSERM, CIC 1413, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000, Nantes, France. Electronic address:

Today's medicine strives to be personalized, preventive, predictive and participatory. This implies to have access to multimodal data to better characterize patients groups and to combine clinical and imaging data with high-quality biological samples. Collecting such data is one of the objectives of the Observatoire français de la sclérose en plaques (OFSEP), the French MS registry.

View Article and Find Full Text PDF
Article Synopsis
  • * A virtual 3-day hackathon brought together 49 early-career scientists from 12 countries, focusing on building tools and pipelines specifically for PD research, with each team working on one of nine distinct projects.
  • * The hackathon not only generated resources to enhance research but also provided training and networking opportunities, ultimately fostering creative problem-solving and collaboration essential for emerging researchers in data science.
View Article and Find Full Text PDF

Although neurological manifestations and changes in brain volumes have been described in Erdheim-Chester disease (ECD), it remains unknown whether ECD may be associated with psychiatric symptoms and cognitive dysfunctions. We assessed the presence of psychiatric disorders, changes in temperaments and characters, and neuropsychological performances in 32 ECD patients (mean age = 59) younger than 70, not treated with interferon alpha during the last 6 months, and without other serious illnesses. ECD patients exhibited high level of past depressive disorder (80%) and anxiety disorder, especially agoraphobia (29%).

View Article and Find Full Text PDF

Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference.

Neurology

March 2023

From the Service de Neurologie (A.G., F.R., R.C., S.V.), Sclérose en Plaques, Pathologies de La Myéline et Neuro-inflammation, Hôpital Neurologique Pierre-Wertheimer, Hospices Civils de Lyon, Bron; Université de Lyon (A.G., M.R., F.S.), Université Claude Bernard Lyon 1, CNRS, Laboratoire de Biométrie et Biologie Évolutive UMR 5558, Villeurbanne; Service de Biostatistique-Bioinformatique (A.G., M.R., F.S.), Hospices Civils de Lyon; Université de Lyon (F.R., R.C., S.V.), Université Claude Bernard Lyon 1; Observatoire Français de La Sclérose en Plaques (F.R., R.C., S.V.), Centre de Recherche en Neurosciences de Lyon, INSERM 1028 et CNRS UMR; EUGENE DEVIC EDMUS Foundation Against Multiple Sclerosis (F.R., R.C., S.V.), State-approved Foundation, Bron; Nancy University Hospital (M.D.), Department of Neurology, Université de Lorraine, APEMAC; CHU Pontchaillou (E.L.P.), CIC1414 INSERM, Rennes; CHU de Toulouse (J.C.), Hôpital Pierre-Paul Riquet, Department of Neurology, CRC-SEP, Toulouse; Infinity (J.C.), INSERM UMR1291-CNRS UMR5051, Université Toulouse III; CHU de Strasbourg (J.D.S.), Department of Neurology and Clinical Investigation Center, CIC 1434, INSERM 1434; Univ. Bordeaux (A.R.), F-33000 Bordeaux INSERM U1215, Neurocentre Magendie, F-33000 Bordeaux CHU de Bordeaux, Department of Neurology, CIC Bordeaux CIC1401; Département de Neurologie (E.M.), Hôpital Pitié-Salpêtrière, APHP, Paris; Centre de Ressources et de Compétences SEP Paris (E.M.); CHU de Montpellier (P.L.), MS Unit; University of Montpellier (MUSE) (P.L.); CHU Lille (H.Z.), CRCSEP Lille, Univ Lille, U1172; Fondation Rotschild (C. Papeix), Department of Neurology, Paris; CHU de Caen (G.D.), MS Expert Centre, Department of Neurology, Avenue de La Côte-de-Nacre, Normandy University, Caen; Neurology (C.L.-F.), UR2CA, Centre Hospitalier Universitaire Pasteur2, Université Nice Côte d'Azur, Nice; CHU de Dijon (T.M.), Department of Neurology, EA4184; CHU de Nantes (D.A.L.), Service de Neurologie & CIC015 INSERM; CRTI-Inserm U1064 (D.A.L.), Nantes; CHU de Besançon (E.B.), Service de Neurologie; Sorbonne Universités (B.S.), UPMC Paris 06, Brain and Spine Institute, ICM, Hôpital de La Pitié Salpêtrière, Inserm UMR S 1127, CNRS UMR 7225, and Department of Neurology, AP-HP, Saint-Antoine Hospital; CHU Clermont-Ferrand (Pierre Clavelou), Department of Neurology, F-63000 Clermont-Ferrand Université Clermont Auvergne, Inserm, Neuro-Dol, F-63000 Clermont-Ferrand; Department of Neurology (E.T.), Nimes University Hospital; Institut de Génomique Fonctionnelle (E.T.), UMR5203, INSERM 1191, Univ. Montpellier; Hôpital de Poissy (O.H.), Department of Neurology; Aix Marseille Univ (J.P.), APHM, Hôpital de La Timone, Pôle de Neurosciences Cliniques, Service de Neurologie; CHU d'Amiens (A.A.K.), Department of Neurology; CHU Grenoble Alpes (O.C.), Department of Neurology, La Tronche/Grenoble; CHU de Rouen (B.B.), Department of Neurology; CHU de La Martinique (Philippe Cabre), Department of Neurology, Fort-de-France; APHP (A.W.), Hôpital Henri Mondor, Department of Neurology, Créteil; CHU de Limoges (L.M.), Hôpital Dupuytren, Department of Neurology; CHU de Saint-Étienne (J.-P.C.), Hôpital Nord, Department of Neurology; CHU de Tours (A.M.), Hôpital Bretonneau, CRC SEP and Department of Neurology; CHU de Reims (S.M.), CRC-SEP, Department of Neurology; Hôpital Sud Francilien (N.H.B.), Department of Neurology, Corbeil Essonnes; CHU Bicêtre (D.D.B.), Department of Neurology, Le Kremlin Bicêtre; Department of Neurology (K.H.), Hôpital Pierre Delafontaine, Centre Hospitalier de Saint-Denis; CHU La Milétrie (J.-P.N.), Hôpital Jean Bernard, Department of Neurology, Poitiers; CH de Pontoise (C. Pottier), Hôpital René Dubos, Department of Neurology; and Centre Hospitalier de Versailles (C.N.), Department of Neurology, F-78150 Le Chesnay, France.

Background And Objectives: The question of the long-term safety of pregnancy is a major concern in patients with multiple sclerosis (MS), but its study is biased by reverse causation (women with higher disability are less likely to experience pregnancy). Using a causal inference approach, we aimed to estimate the unbiased long-term effects of pregnancy on disability and relapse risk in patients with MS and secondarily the short-term effects (during the perpartum and postpartum years) and delayed effects (occurring beyond 1 year after delivery).

Methods: We conducted an observational cohort study with data from patients with MS followed in the Observatoire Français de la Sclérose en Plaques registry between 1990 and 2020.

View Article and Find Full Text PDF

Background: In relapsing-remitting multiple sclerosis (RRMS), early identification of suboptimal responders can prevent disability progression.

Objective: We aimed to develop and validate a dynamic score to guide the early decision to switch from first- to second-line therapy.

Methods: Using time-dependent propensity scores (PS) from a French cohort of 12,823 patients with RRMS, we constructed one training and two validation PS-matched cohorts to compare the switched patients to second-line treatment and the maintained patients.

View Article and Find Full Text PDF

To ensure survival in a dynamic environment, the human neocortex monitors input streams from different sensory organs for important sensory events. Which principles govern whether different senses share common or modality-specific brain networks for sensory target detection? We examined whether complex targets evoke sustained supramodal activity while simple targets rely on modality-specific networks with short-lived supramodal contributions. In a series of hierarchical multisensory target detection studies ( = 77, of either sex) using EEG, we applied a temporal cross-decoding approach to dissociate supramodal and modality-specific cortical dynamics elicited by rule-based global and feature-based local sensory deviations within and between the visual, somatosensory, and auditory modality.

View Article and Find Full Text PDF

Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.

Neurology

October 2022

From the CORe (I.R., C.M., T.K.), Department of Medicine, University of Melbourne, Australia; Melbourne MS Centre (I.R., C.M., T.K.), Department of Neurology, Royal Melbourne Hospital, Australia; Rennes, University (E.L.), EHESP, REPERES EA 7449, France; Univ Rennes (E.L.), CHU Rennes, Inserm, CIC 1414 ([Centre d'Investigation Clinique de Rennes]), France; Université de Lyon (R.C.), Université Claude Bernard Lyon 1, France; Hospices Civils de Lyon (R.C.), Service de Neurologie, Sclérose en Plaques, Pathologies de La Myéline et Neuro-inflammation, Bron, France; Observatoire Français de La Sclérose en Plaques (R.C.), Centre de Recherche en Neurosciences de Lyon, INSERM 1028 et CNRS UMR 5292, France; Eugène Devic EDMUS Foundation Against Multiple Sclerosis (R.C.), State-approved Foundation, Bron, France; Department of Neurology and Center of Clinical Neuroscience (D.H., E.K.H.), First Faculty of Medicine, Charles University in Prague and General University Hospital, Czech Republic; Nancy University Hospital (M.D.), Department of Neurology, Nancy, France; Université de Lorraine (M.D.), APEMAC, Nancy, France; Department of Medical and Surgical Sciences and Advanced Technologies (F.P.), GF Ingrassia, Catania, Italy; Multiple Sclerosis Center (F.P.), University of Catania, Italy; CHU de Strasbourg (J.D.S.), Department of Neurology and Clinical Investigation Center, CIC 1434, INSERM 1434, Strasbourg, France; Hospital Universitario Virgen Macarena (G.I., S.E.), Sevilla, Spain; CHU Pontchaillou (G.E.), CIC1414 INSERM, Rennes, France; CHUM MS Center and Universite de Montreal (A.P., M.G.), Canada; Dokuz Eylul University (S.O.), Konak/Izmir, Turkey; CISSS Chaudière-Appalache (P.G.), Levis, Canada; CHU Lille (H.Z.), CRCSEP Lille, Univ Lille, U1172, France; CHU de Toulouse (J.C.), Hôpital Pierre-Paul Riquet, Department of Neurology, CRC-SEP, France; Département de Neurologie (E.M.), Hôpital Pitié-Salpêtrière, APHP, Paris; CHU de Dijon (T.M.), Department of Neurology, EA4184, France; Department NEUROFARBA (M.P.A.), University of Florence, Italy; CHU de Montpellier (P.L.), MS Unit, France; University of Montpellier (MUSE) (P.L.), France; Division of Neurology (Raed Alroughani), Department of Medicine, Amiri Hospital, Sharq, Kuwait; Department of Neurology (K.B., O.S.), Box Hill Hospital, Melbourne, Australia; Monash University (K.B., O.S.), Melbourne, Australia; Melbourne MS Centre (K.B.), Royal Melbourne Hospital, Australia; The Alfred Hospital (O.S.), Melbourne, Australia; Medical Faculty (M.T.), 19 Mayis University, Samsun, Turkey; CHU de Nantes (D.A.L.), Service de Neurologie & CIC015 INSERM, France; CRTI-Inserm U1064 (D.A.L.), Nantes, France; CHU de Besançon (E.B.), Service de Neurologie 25 030 Besançon, France; Neuro Rive-Sud (F.G.M.), Quebec, Canada; Neurology (C.L.-F.), UR2CA, Centre Hospitalier Universitaire Pasteur2, Université Nice Côte d'Azur, Nice, France; UOC Neurologia (E.C.), Azienda Sanitaria Unica Regionale Marche-AV3, Macerata, Italy; KTU Medical Faculty Farabi Hospital (C.B.), Trabzon, Turkey; School of Medicine and Public Health (J.L.-S.), University Newcastle, Australia; Department of Neurology (J.L.-S.), John Hunter Hospital, Hunter New England Health, Newcastle, Australia; CHU Clermont-Ferrand (Pierre Clavelou), Department of Neurology; Université Clermont Auvergne, Inserm, Neuro-Dol, Clermont-Ferrand, France; Sorbonne Universités (B.S.), UPMC Paris 06, Brain and Spine Institute, ICM, Hôpital de La Pitié Salpêtrière, Inserm UMR S 1127, CNRS UMR 7225, and Department of Neurology, AP-HP, Saint-Antoine Hospital, Paris, France; CSSS Saint-Jérôme (Julie Prevost), Saint-Jerome, Canada; Neurologic Clinic and Policlinic (L.K.), Departments of Medicine and Clinical Research, University Hospital and University of Basel, Switzerland; Aix Marseille Univ (Jean Pelletier), APHM, Hôpital de La Timone, Pôle de Neurosciences Cliniques, Service de Neurologie, France; Isfahan University of Medical Sciences (V.S.), Iran; Nehme and Therese Tohme Multiple Sclerosis Center (B.I.Y., S.J.K.), American University of Beirut Medical Center, Beirut, Lebanon; Department of Neurology (Oliver Gerlach), Zuyderland Medical Center, Sittard-Geleen, Netherlands; Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino (D.L.A.S.), Italy; Cliniques Universitaires Saint-Luc (V.V.P.), Université Catholique de Louvain, Brussels, Belgium; Fondation Rotschild (Olivier Gout), Department of Neurology, Paris, France; Haydarpasa Numune Training and Research Hospital (R.T.), Istanbul, Turkey; Hôpital de Poissy (O.H.), Department of Neurology, France; Department of Neurology (E.T.), Nimes University Hospital, France; Institut de Génomique Fonctionnelle (E.T.), UMR5203, INSERM 1191, Univ. Montpellier, France; University of Queensland (P.A.M.), Brisbane, Australia; Royal Brisbane and Women's Hospital (P.A.M.), Australia; Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases (A.S.), Istanbul, Turkey; CHU de Rouen (B.B.), Department of Neurology, France; Flinders University (M.S.), Adelaide, Australia; Instituto de Investigación Sanitaria Biodonostia (T.C.-T.), Hospital Universitario Donostia, San Sebastián, Spain; CHU de Reims (S.B.), Department of Neurology, France; Nemocnice Jihlava (Radek Ampapa), Czech Republic; Monash Medical Centre (E.G.B.), Melbourne, Australia; APHP (A.W.), Hôpital Henri Mondor, Department of Neurology, Créteil, France; Austin Health (R.A.M.), Melbourne, Australia; University Hospital Reina Sofia (E.A.-M.), Cordoba, Spain; CHU de La Martinique (Philippe Cabre), Department of Neurology, Fort-de-France, France; Hôpital Sud Francilien (N.H.B.), Department of Neurology, Corbeil Essonnes, France; Department of Neurology (A.V.W., H.B.), The Alfred Hospital, Melbourne, Australia; Central Clinical School (A.V.W., H.B.), Monash University, Melbourne, Australia; Department of Neurology (G.L., L.V.H.), University Hospital Ghent, Belgium; Hospital Germans Trias I Pujol (C.M.R.-T.), Badalona, Spain; CHU La Milétrie (N.M.), Hôpital Jean Bernard, Department of Neurology, Poitiers, France; Liverpool Hospital (S.H.), Sydney, Australia; Hospital de Galdakao-Usansolo (J.L.S.-M.), Spain; Brain and Mind Centre (M.H.B.), Sydney, Australia; CHU Bicêtre (C.L.), Department of Neurology, F-94275 Le Kremlin Bicêtre, France; Westmead Hospital (Steve Vucic), Sydney, Australia; Department of Neurology (Y.S., R.G.), Razi Hospital, Manouba, Tunisia; Department of Neurology (T.C.), Faculty of Medicine, University of Debrecen, Hungary; Hospital Universitari MútuaTerrassa (J.S.), Barcelona, Spain; Groene Hart Ziekenhuis (K.G.), Gouda, Netherlands; Sultan Qaboos University Hospital (A.A.-A.), Al-Khodh, Oman; Universidade Metropolitana de Santos (Y.D.F.), Santos, Brazil; Service de Neurologie (Sandra Vukusic), Sclérose en Plaques, Pathologies de La Myéline et Neuro-inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France; Centre des Neurosciences de Lyon (Sandra Vukusic), Observatoire Français de La Sclérose en Plaques, INSERM 1028 et CNRS UMR5292, France; and Université Claude Bernard Lyon 1 (Sandra Vukusic), Faculté de Médecine Lyon Est, France.

Article Synopsis
  • This study evaluates the rate of disease activity return in multiple sclerosis (MS) patients after they stop using disease-modifying therapy, focusing on relapse rates and factors influencing relapse.
  • A large sample of 14,213 patients showed that relapse rates typically increased within 2 months after stopping treatment, with earlier commencement of new therapy reducing these rates significantly.
  • Factors predicting relapse included having a higher relapse rate prior to stopping therapy, being younger, being female, and having a higher Expanded Disability Status Scale (EDSS) score, with subsequent therapy reducing both relapse risk and disability progression.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to analyze how epilepsy develops in patients with LGI1 antibody-associated limbic encephalitis and to identify factors linked to drug-resistant epilepsy (DRE).
  • Researchers conducted a retrospective review of 39 patients' medical data from two epilepsy centers over a 14-year period, focusing on seizure history and responses to anti-seizure medications.
  • Results showed that 28% of patients achieved epilepsy remission, with longer delays in starting treatment linked to persistent epilepsy, while MRI changes, especially hippocampal atrophy, were main predictors of developing DRE.
View Article and Find Full Text PDF

Features of resting brain metabolism in motor functional neurological disorder are poorly characterized. This study aimed to investigate the alterations of resting brain metabolism in a cohort of patients experiencing a first episode of motor functional neurological disorder with recent symptom onset and their association with persistent disability after 3 months. Patients eligible for inclusion were diagnosed with first episode of motor functional neurological disorder, were free from bipolar disorder, substance use disorder, schizophrenia, psychogenic non-epileptic seizure or any chronic or acute organic neurological disorder.

View Article and Find Full Text PDF

Face-selective multi-unit activity in the proximity of the FFA modulated by facial expression stimuli.

Neuropsychologia

June 2022

Institut National de La Santé et de La Recherche Médicale Unité 1127, Centre National de La Recherche Scientifique Unité Mixte de Recherche (UMR) 7225, Université Pierre-et-Marie-Curie Univ Paris 06 UMR S 1127, Institut Du Cerveau et de La Moelle Épinière ICM, 75013, Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Neurophysiology, 75013, 47-83, Boulevard de L'Hôpital, Paris, France.

When we see someone's face, our brain usually effortlessly extracts a variety of information such as facial identity, expression, or gaze direction. While it is widely accepted that dedicated subsystems are responsible for different aspects of face processing, how these subsystems work together is not yet fully understood. To this extent, one of the most explored questions is whether and if so, to what extent facial expression processing interacts with other stages of facial processing.

View Article and Find Full Text PDF

Subtle postoperative cognitive disorder in preclinical Alzheimer's disease.

Exp Gerontol

May 2022

Institute of Memory and Alzheimer's Disease (IM2A) and Brain and Spine Institute (ICM) UMR S 1127, Inria, Aramis-project Team, APHP-Inria Collaboration, Paris, France; Department of Neurology, AP-HP, Pitié-Salpêtrière University Hospital, Sorbonne Universities, Pierre et Marie Curie University, Paris 06, Paris, France(2). Electronic address:

Background: We examined the association between preclinical Alzheimer's disease (AD) and undergoing anesthesia and surgery ("surgery" henceforth) in a cohort of elderly individuals with a subjective cognitive decline (SCD).

Methods: Individuals with SCD (N = 268) were enrolled in a longitudinal follow-up study. Participants underwent comprehensive yearly cognitive evaluation for a period of 4 years.

View Article and Find Full Text PDF

Coffee consumption and seizure frequency in patients with drug-resistant focal epilepsy.

Epilepsy Behav

January 2022

Department of Functional Neurology and Epileptology, Hospices Civils de Lyon and University of Lyon, Lyon, France; Lyon's Neuroscience Research Center, INSERM U1028 / CNRS UMR 5292 and Lyon 1 University, Lyon, France; Epilepsy Institute, Lyon, France. Electronic address:

Objective: To assess the relation between coffee consumption and seizure frequency in patients with drug-resistant focal epilepsy.

Methods: Cross-sectional analysis of data collected in the SAVE study, which included patients with drug-resistant focal epilepsy during long-term EEG monitoring. Patients in whom both coffee consumption and data about seizure frequency, including focal to bilateral tonic-clonic seizures (FBTCS), were available were selected.

View Article and Find Full Text PDF

Stress response in dissociation and conversion disorders: A systematic review.

Neurosci Biobehav Rev

January 2022

Department of Psychiatry, Nîmes University Hospital, Nîmes, France; IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France; Centre de Biochimie Structurale, University of Montpellier, Montpellier, France. Electronic address:

Dissociative disorders (DD) and conversion disorders (CD) are frequent in general and psychiatric populations. Some evidence suggest that the hypothalamic-pituitary axis (HPA) and autonomic nervous system (ANS) are dysregulated in both disorders. We carried out a systematic review of the literature to summarize the existing knowledge on the stress response, via HPA and/or ANS, in patients with DD, CD, or dissociative symptoms.

View Article and Find Full Text PDF

Low-Coverage Whole Genome Sequencing of Cell-Free DNA From Immunosuppressed Cancer Patients Enables Tumor Fraction Determination and Reveals Relevant Copy Number Alterations.

Front Cell Dev Biol

August 2021

Sorbonne University, INSERM, Research Unit on Cardiovascular and Metabolic Disease UMR ICAN, Department of Endocrine Biochemistry and Oncology, AP-HP, Hôpital Pitié Salpêtrière, Paris, France.

Article Synopsis
  • Cell-free DNA (cfDNA) analysis is a blood-based method that helps identify genetic abnormalities, especially beneficial for immunosuppressed patients who cannot undergo traditional biopsies.
  • In our study, we analyzed cfDNA from 36 patients with rare cancers, revealing tumor fractions (TF) in 29% of immunosuppressed patients with specific cancers, and successfully correlated cfDNA profiles with tumor tissue.
  • The use of low-coverage whole genome sequencing (LC-WGS) proved to be an efficient approach for detecting genetic content in cfDNA, aiding in the molecular analysis for better treatment strategies.
View Article and Find Full Text PDF

Language improvement characteristics post-cranioplasty : a single case study.

Ann Phys Rehabil Med

May 2022

AP-HP, La Pitié-Salpêtrière - Charles Foix University Hospital, Department of Physical and Rehabilitation Medicine, F-75013, Paris, France; Sorbonne Université, GRC n°24, Handicap Moteur et Cognitif & Réadaptation (HaMCRe), AP-HP. Sorbonne Université, F-75013, Paris, France; Brain and Spine Institute (ICM; INSERM, UMRS 1127; CNRS, UMR 7225), Paris, France. Electronic address:

View Article and Find Full Text PDF